GTC
ALDX icon

Ghost Tree Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Ghost Tree Capital’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300,000
Closed -$1.2M – 43
2021
Q4 		$1.2M Buy
+300,000
New +$2.29M 0.43% 44

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ghost Tree Capital's ALDX Position: Q4 2021 in Review

Ghost Tree Capital sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 700,000 shares — an estimated $5.34M sold.

Ghost Tree Capital first reported a position in ALDX in Q2 2020 and held it in 6 quarters. The position peaked at $9.26M in Q3 2020. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

  • Ghost Tree Capital reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Ghost Tree Capital sold 700,000 Aldeyra Therapeutics shares in Q4 2021, an estimated $5.34M.
  • Ghost Tree Capital first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 6 quarters.
  • Ghost Tree Capital's Aldeyra Therapeutics position peaked at $9.26M in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.